Community-based referral for tuberculosis preventive therapy is effective for treatment completion

Datos Bibliográficos

ID19591926
AutoresSheela V Shenoi (0000-0001-7654-4344, Yale University, autor de correspondencia), Tassos C Kyriakides (0000-0001-8913-108X), E Kainne Dokubo (0000-0002-1499-0151, Centers for Disease Control and Prevention), Vijayanand Guddera (South African Medical Research Council), Peter Vranken (University of Pretoria), Mitesh Desai (0000-0002-2629-5666, Centers for Disease Control and Prevention), Gerald Friedland (0000-0002-9400-6539, Yale University), Anthony P Moll (Philanjalo)
EditoresAndrew D Kerkhoff (0000-0002-5023-6658)
Año2022
Volumen2
Número12
Páginase0001269
Fecha de publicación2022-12-14
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaPLOS Global Public Health (JOURNAL)
Identificadores de la revistaISSN: 2767-3375 • E-ISSN: 2767-3375
EditorialPublic Library of Science (PLoS) (PUBLISHER)
DOI10.1371/journal.pgph.0001269
PMID36962910
OpenAlexW4311439658
IdiomaEN
Citas recibidas1
Referencias citadas57

Expansion of tuberculous preventive therapy (TPT) is essential to curb TB incidence and mortality among people with HIV (PWH), yet implementation has been slow. Innovative strategies to operationalize TPT are urgently needed. Here we present an evaluation of community-based identification and referral of PWH on completion of a six-month course of isoniazid in a highly prevalent region in rural South Africa. Using a community-based TB/HIV intensive case finding strategy, a team of nurses and lay workers identified community members with HIV who were without fever, night sweats, weight loss, or cough and referred them to the government primary care clinics for daily oral isoniazid, the only available TPT regimen. We measured monthly adherence and six-month treatment completion in the community-based identification and referral (CBR) group compared to those already engaged in HIV care. Adherence was measured by self-report and urine isoniazid metabolite testing. A multivariable analysis was performed to identify independent predictors of TPT completion. Among 240 participants, 81.7% were female, median age 35 years (IQR 30–44), and 24.6% had previously been treated for TB. The median CD4 count in the CBR group was 457 (IQR 301–648), significantly higher than the clinic-based comparison group median CD4 of 344 (IQR 186–495, p

Directly Observed Therapy · Family medicine · Isoniazid · Referral · Regimen · Tuberculosis · HIV/AIDS Research and Interventions · Medicine · Pneumocystis jirovecii pneumonia detection and treatment · Tuberculosis Research and Epidemiology · Internal Medicine · Pediatrics